
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences is an oncology-focused precision medicine company with a positive outlook due to its extensive small molecule drug discovery and targeted therapy development capabilities, as well as its multiple clinical-stage product candidates. Its potential for commercial success is supported by its plans for NDA submission and potential off-label use of darovasertib for HLA-A*02:01-positive mUM, strong OS data in earlier trials, and high unmet need in this patient population. Risks include clinical and regulatory failure and competition in the mUM market, but the company's focus on HLA+ patients, potential differentiation from current therapies, and positive KOL feedback are reasons for optimism.
Bears say
IDEAYA Biosciences is an oncology-focused precision medicine company with multiple product candidates in clinical and preclinical stages of development. However, the company's stock should be approached with caution due to high potential competition and relatively low financial prospects with an estimated total addressable market of only $250 million for their main product candidate. Additionally, despite positive trial results, the lack of pivotal OS data and a potential off-label use for HLA-A*02:01-positive patients may cause near-term debates and uncertainty about the success and potential market impact of their lead asset darovasertib.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares